Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 12, 2025
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTSW (11/26/2025, 8:27:27 PM)
0.3425
+0 (+0.74%)
NASDAQ:DRTS (11/28/2025, 8:24:31 PM)
3.97
+0.23 (+6.15%)
Find more stocks in the Stock Screener
